Cytosorbents (CTSO) Projected to Post Quarterly Earnings on Wednesday

Cytosorbents (NASDAQ:CTSO) will likely be releasing its Q4 2025 results before the market opens on Wednesday, March 11th. Analysts expect Cytosorbents to post earnings of ($0.05) per share and revenue of $9.78 million for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, March 11, 2026 at 4:00 PM ET.

Cytosorbents Stock Performance

Shares of NASDAQ CTSO opened at $0.80 on Wednesday. Cytosorbents has a 1 year low of $0.60 and a 1 year high of $1.39. The firm has a market cap of $50.24 million, a P/E ratio of -4.44 and a beta of 1.36. The stock has a fifty day moving average price of $0.68 and a two-hundred day moving average price of $0.78. The company has a debt-to-equity ratio of 1.61, a quick ratio of 1.71 and a current ratio of 2.11.

Analysts Set New Price Targets

A number of research firms recently commented on CTSO. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cytosorbents in a research note on Friday, January 9th. HC Wainwright decreased their target price on Cytosorbents from $1.00 to $0.75 and set a “neutral” rating for the company in a research report on Friday, November 14th. Finally, D. Boral Capital reissued a “buy” rating and set a $10.00 price target on shares of Cytosorbents in a research report on Monday, January 12th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Cytosorbents currently has a consensus rating of “Hold” and an average target price of $5.38.

Hedge Funds Weigh In On Cytosorbents

Institutional investors have recently modified their holdings of the company. Goldman Sachs Group Inc. lifted its position in Cytosorbents by 149.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock worth $63,000 after acquiring an additional 37,519 shares during the last quarter. Citadel Advisors LLC increased its stake in shares of Cytosorbents by 127.3% in the third quarter. Citadel Advisors LLC now owns 65,690 shares of the medical research company’s stock worth $61,000 after purchasing an additional 36,790 shares during the period. CIBC Bancorp USA Inc. acquired a new position in shares of Cytosorbents during the 3rd quarter worth about $161,000. Vanguard Group Inc. lifted its position in shares of Cytosorbents by 3.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,204,294 shares of the medical research company’s stock worth $2,059,000 after purchasing an additional 79,535 shares during the last quarter. Finally, Avenir Corp boosted its stake in Cytosorbents by 2.9% during the 4th quarter. Avenir Corp now owns 5,230,099 shares of the medical research company’s stock valued at $3,343,000 after purchasing an additional 147,261 shares during the period. Institutional investors own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.